New research suggests that the adoption of statewide laws regulating cannabis products for patients and adults is associated with significant declines in non-fatal opioid-related overdoses. This analysis, published in the journal Preventive Medicine Reports, adds to a growing body of evidence exploring the relationship between cannabis legalisation and public health outcomes.
Researchers affiliated with the University of Kentucky Department of Health examined data from a large cohort of over 107 million adults enrolled in employer-sponsored health insurance plans across all 50 states. Their objective was to assess the connection between cannabis legalisation laws and rates of non-fatal opioid-related overdoses.
Understanding the Research on Cannabis Legalisation and Opioid Overdoses
The study defined non-fatal overdoses as instances requiring hospital care for “poisoning or accidental poisoning by opium, heroin, methadone, and other opiates and related narcotics, and the adverse effects of opium, heroin, methadone, and other opiates and related narcotics.” This comprehensive definition allowed investigators to capture a broad range of opioid-related incidents.
According to the findings reported by NORML, investigators determined that non-fatal overdoses decreased after states regulated cannabis access. Specifically:
- The opening of medical cannabis dispensaries (MCD) was associated with a 15.47 percent reduction in non-fatal opioid poisoning diagnoses (NF-OPD).
- The enactment of recreational cannabis laws (RCL) was associated with an 11.92 percent reduction in NF-OPD.
These reductions suggest a potential link between increased access to cannabis and a decrease in certain opioid-related health incidents.
Key Findings and Patient Demographics
The study further detailed the demographics among whom these reductions were observed:
- Reductions related to medical cannabis dispensary openings were significant among males and females, adults aged 18–44, outpatients, and individuals without a history of prescription opioid or cannabis use disorder in the past year.
- Reductions related to recreational cannabis laws were significant among outpatients and those without prescription opioid or cannabis use disorder in the past year.
The study’s authors concluded that “expanded access to cannabis through MCD and RCL is associated with lower NF-OPD among adults with employer-sponsored insurance, particularly among males and younger adults, who are disproportionately affected by the opioid epidemic.” These findings align with other research that has explored connections between legal cannabis access and reductions in opioid use, prescriptions, hospitalisations, and overdose deaths.
Implications for Public Health
The potential role of medicinal cannabis in public health strategies, particularly concerning opioid use, continues to be an area of significant scientific interest. Paul Armentano, NORML’s Deputy Director, commented on the findings, stating that they “add to the already robust evidence documenting the opioid-sparing effects of cannabis and highlight the role legal cannabis access can play in mitigating the public health burden associated with the use of prescription and non-prescription opiates.”
While this study provides valuable insights into the association between cannabis legalisation and non-fatal opioid overdoses, further research is ongoing to understand the full scope of cannabinoids’ pharmacological interactions and their potential applications in various health contexts.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
